Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Angel Guerrero Zotano"'
Autor:
Komal Jhaveri, Haeseong Park, James Waisman, Jonathan W Goldman, Angel Guerrero-Zotano, Valentina Boni, Barbara Haley, Ingrid A Mayer, Adam Brufsky, Eddy S Yang, José A García-Sáenz, François-Clement Bidard, John Crown, Bo Zhang, Aimee Frazier, Irmina Diala, Lisa D Eli, Brian Barnett, Hans Wildiers
Publikováno v:
Cancer Research. 82:GS4-10
Background: HER2 mutations are oncogenic drivers in a subset of metastatic breast cancers (MBC). Neratinib (N) is an oral, irreversible pan-HER tyrosine kinase inhibitor with preclinical and clinical activity against HER2 mutations. Genomic analyses
Autor:
John Crown, Jonathan W. Goldman, Stephen Chia, Jennifer Marie Suga, Ingrid A. Mayer, Lucía González-Cortijo, Sofia Wong, Cristina Saura, Bruno Perrucci, Alshad S. Lalani, Feng Xu, Andrés Cervantes, Angel Guerrero-Zotano, Valentina Boni, Lisa D. Eli, Komal Jhaveri, Noa Ben-Baruch, François-Clément Bidard, James Waisman, José A. García-Sáenz, Jie Zhang, Barbara Haley, Adam Brufsky, Sherene Loi, Janice Lu, Iben Spanggaard, Mark E. Burkard, Hans Wildiers
Publikováno v:
Cancer Research. 81:PD1-05
Background: HER2 mutations are oncogenic in hormone receptor positive (HR+) metastatic breast cancer (MBC), and may confer resistance to prior endocrine therapy but retain sensitivity to neratinib. Neratinib is an oral, irreversible, pan-HER tyrosine
Autor:
Mellissa J. Nixon, Sarah Croessmann, Justin M. Balko, Carlos L. Arteaga, Paula Gonzalez Ericsson, Alshad S. Lalani, Melinda E. Sanders, Dhivya R. Sudhan, Francesca Avogadri-Connors, Angel Guerrero-Zotano, Alan Auerbach, Richard Bryce, Luigi Formisano, Luis J. Schwarz, Richard E. Cutler
Publikováno v:
Clinical Cancer Research. 25:771-783
Purpose:The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater
Autor:
Susana García-Recio, Vincenzo Adamo, Patricia Galván, Octavio Burgués Gasión, Eduardo Martínez de Dueñas, Rosalia Caballero, Laia Paré, Federico Rojo, Maria Vidal, Ramon Perez, Aleix Prat, Charles M. Perou, Ana Lluch, Eva Carrasco, Roger R. Gomis, Rossella Martinello, Javier Cortes, Juan Miguel Cejalvo, Paolo Nuciforo, Angel Guerrero-Zotano, Barbara Adamo, Silvia Antolín, Vicente Peg, I. Blancas, Montserrat Muñoz, Joan Albanell, Jose Ignacio Chacon Lopez-Muniz
Publikováno v:
Cancer Research
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
CANCER RESEARCH
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
CANCER RESEARCH
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d585344d4f88d1666f4549688175c2d
https://europepmc.org/articles/pmc5822682?pdf=render
https://europepmc.org/articles/pmc5822682?pdf=render
Autor:
Monica V. Estrada, Melinda E. Sanders, Christian D. Young, Monica Red-Brewer, Michael Kragh, Katherine E. Hutchinson, Carlos L. Arteaga, Teresa C. Dugger, Mikkel Wandahl Pedersen, Brent N. Rexer, Paula Gonzalez Ericsson, Angel Guerrero-Zotano, Luis J. Schwarz, Johan Lantto, Ivan D Horak, Luigi Formisano
BACKGROUND: Plasticity of the ERBB receptor network has been suggested to cause acquired resistance to anti–human epidermal growth factor receptor 2 (HER2) therapies. Thus, we studied whether a novel approach using an ERBB1-3-neutralizing antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bd3794dbce2dda63c3562556360f45
http://hdl.handle.net/11588/698505
http://hdl.handle.net/11588/698505
Autor:
Cristina Cruz Zambrano, Susana Bezares, Juan de la Haba, Barbara Adamo, Santiago Gonzalez Santiago, Raquel Andrés, Montserrat Muñoz, Sonia Alonso Soler, Vanesa García, M Melé, Federico Rojo, Sebastian Moran Salama, Nuria Martin, M. J. Escudero, Manel Esteller, Sonia Servitja, Sara López-Tarruella, Rosalia Caballero, Jose Alejandro Perez-Fidalgo, Angel Guerrero-Zotano
Publikováno v:
Journal of Clinical Oncology. 36:TPS1114-TPS1114
TPS1114Background: Identification of targeted therapies for advanced triple negative breast cancer (TNBC) remains as an important clinical challenge. TNBC frequently shows BRCA dysfunction and 80% ...